Company news

Esperion Therapeutics, Inc. (NASDAQ:ESPR) news

Esperion Therapeutics, Inc. news releases on 6ix. Latest, Sep 30, 2026: Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before…

Esperion Therapeutics, Inc. (NASDAQ:ESPR) news

Press releases & updates

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion to be Acquired by ARCHIMED

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

/C O R R E C T I O N -- HLS Therapeutics Inc./

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Esperion to Participate in Jefferies Global Healthcare Conference - London

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Esperion to Report Third Quarter 2025 Financial Results on November 6

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

Esperion Announces Proposed Public Offering of Common Stock

Esperion Announces Pricing of Public Offering of Common Stock

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Oritain Extends Cutting-Edge Origin Verification to Leather for EUDR Readiness

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Esperion to Participate in Upcoming September Investor Conferences

HLS Therapeutics Announces Q2 2025 Financial Results

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Esperion to Report Second Quarter 2025 Financial Results on August 5

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion Appoints Craig Thompson to Board of Directors

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Participate in Upcoming June Investor Conferences

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference